MedTrace Logo

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH

NCT05738083 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-04-30

No results posted yet for this study

Summary

PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage

Interventions

DIAGNOSTIC_TEST

Machine Leaning Models

Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance. Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made. Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes. Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model. Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model.

Sponsors & Collaborators

  • Panzhihua Central Hospital

    collaborator OTHER

  • Zhujiang Hospital

    collaborator OTHER

  • Southwest Hospital, China

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    lead OTHER

Principal Investigators

  • Xingen Zhu, Prof · Second Affiliated Hospital of Nanchang University

  • Qianxue Chen, Prof · Renmin Hospital of Wuhan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2028-12-30
Completion
2029-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05738083 on ClinicalTrials.gov